8-K: Vivos Therapeutics Acquires Stake in SOD Sciences IP

Vivos Therapeutics closes acquisition of an 11% equity interest in SOD Sciences and a 50% co-ownership interest in its pseudohypoxia early-warning test, aiming to expand patient reach and services.

Summary

• Vivos Therapeutics, Inc. has completed the acquisition of an 11% equity interest in SOD Sciences, Inc. (SOD) and a 50% undivided co-ownership interest in SOD's pseudohypoxia early-warning test (the Test IP).
• In exchange, Vivos issued 12,000 shares of Series C Convertible Preferred Stock to SOD, with an aggregate stated value of $12 million.
• This transaction is expected to add over $10 million to Vivos' stockholders' equity.
• The co-ownership agreement stipulates a 50/50 split of all revenue and consideration from the exploitation of the Test IP, as well as equal sharing of patent prosecution, maintenance, and defense costs.
• Vivos anticipates potential access to over 325,000 new patients through SOD's marketing relationship with American Health Associates (AHA), subject to definitive agreements and bankruptcy court approval.
• The company believes this acquisition could be transformational, expanding its market and services to patients at high risk for Obstructive Sleep Apnea (OSA) and related chronic diseases.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating strategic expansion and potential for significant revenue growth, though contingent on future agreements and approvals.

Positives

• Acquisition of a 50% co-ownership interest in the pseudohypoxia early-warning test (Test IP), potentially enhancing diagnostic capabilities.
• Expected increase of over $10 million in stockholders' equity, which may help Vivos regain compliance with Nasdaq's minimum stockholders equity requirement.
• Potential access to a significant new patient pool of over 325,000 through SOD's relationship with American Health Associates (AHA), subject to further agreements and approvals.
• Strategic alignment with SOD Sciences is expected to provide new diagnostic and therapy products synergistic with Vivos' existing OSA treatment methods.
• Access to established distribution channels, including Cleveland Clinic Weston and AHA, is anticipated.
• The transaction was structured as a stock-for-stock exchange, with no cash consideration paid by either party.

Negatives

• The potential access to the AHA patient channel is contingent on the negotiation and execution of definitive agreements and final approval of AHA's pending bankruptcy proceeding.
• The pseudohypoxia test's clinical utility, validation, regulatory status, and commercial potential are subject to further development and may not be realized.
• Conversion of the Series C Convertible Preferred Stock could lead to dilution for existing common stockholders.
• The company's compliance with Nasdaq's continued listing requirements is subject to ongoing monitoring and review by Nasdaq.

Risks

• The Company may not regain or maintain compliance with Nasdaq's continued listing requirements.
• Stockholder approval for issuing common stock in excess of the Exchange Cap (19.99%) may not be obtained.
• The accounting treatment of the Series C Preferred Stock and acquired interests may differ from anticipated conclusions by the independent registered public accounting firm or Nasdaq.
• Definitive agreements with AHA and Cleveland Clinic Weston may not be executed on anticipated terms or at all.
• AHA may not emerge from bankruptcy, or the bankruptcy court may not approve the contemplated arrangements.
• The pseudohypoxia test may not achieve clinical validation, regulatory clearance, or market acceptance.
• Anticipated revenue, margin, and other benefits of the transaction may not be realized.
• Conversion of Series C Preferred Stock could result in dilution to existing stockholders.

Future Outlook

Vivos Therapeutics anticipates that the acquisition of the pseudohypoxia test IP and the strategic alliance with SOD Sciences will be transformational, expanding its market and services to hundreds of thousands of new patients at high risk for OSA and related chronic diseases. The company expects to negotiate joint marketing agreements and potentially generate significant revenue from the AHA channel starting in 2027, with limited capital outlay. The company also believes it has regained compliance with Nasdaq's minimum stockholders equity requirement.

Management Comments

• "Today Vivos became more than a healthcare company just treating sleep apnea," said R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos.
• "We expect this transaction to add more than $10 million to our stockholders equity, and we now own half of a test designed to identify patients whose sleep apnea may be contributing to chronic disease."
• "With more than 2,600 sleep centers in the country and SODs channel partners behind us, we intend to take that test nationwide, and our FDA-cleared appliances treat the obstructive sleep apnea that may be contributing to the condition the test is designed to identify."
• Management believes that, if definitive agreements with AHA are executed and the channel is implemented as contemplated, the AHA channel could represent a meaningful, potentially multi-million dollar, OSA sleep testing revenue opportunity for Vivos beginning in 2027, with limited capital and staffing outlays from Vivos.

Industry Context

StockSavvy.ai notes that this transaction aligns with a broader trend in the healthcare technology sector where companies are seeking to integrate diagnostic tools with treatment platforms to offer more comprehensive patient care. The focus on early detection of chronic diseases linked to sleep apnea is a growing area of interest.

Comparison to Industry Standards

• The transaction structure, involving an equity stake and co-ownership of intellectual property in exchange for preferred stock, is a common method for strategic partnerships in the biotech and medtech sectors.
• The potential patient reach through the AHA channel (over 325,000 patients) is significant and comparable to large-scale patient acquisition strategies seen in established healthcare service providers.
• The expected increase in stockholders equity aims to address Nasdaq listing requirements, a common challenge for growth-stage companies in the sector, where maintaining minimum equity is crucial for continued listing.

Legal Proceedings

• American Health Associates (AHA) is currently in a pending bankruptcy proceeding, which may affect the finalization of agreements related to patient access.

Related Party Transactions

• Other than the Agreement, the Assignment Agreement, and the transactions contemplated thereby, there is no material relationship between Vivos or its affiliates and SOD Sciences.

Stakeholder Impact

• Shareholders: Potential for increased equity, expanded market reach, and future revenue growth, but also risk of dilution from preferred stock conversion and potential delisting if Nasdaq requirements are not met.
• Employees: Potential for company growth and expansion, leading to new opportunities.
• Customers (Patients): Potential for access to new diagnostic tests for chronic diseases linked to sleep apnea and expanded treatment options.
• Suppliers: Potential for increased demand for Vivos' products and services if the strategic alliances are successful.
• Creditors: The company's improved financial standing (expected equity increase) could positively impact its creditworthiness.

Next Steps

• Negotiate a joint marketing agreement with SOD Sciences for the ReBalU Protocol and Vivos' products.
• Negotiate definitive agreements with American Health Associates (AHA) and Cleveland Clinic Weston.
• Obtain final approval from the bankruptcy court for AHA's pending bankruptcy proceeding.
• Seek stockholder approval for the issuance of shares of Common Stock in excess of the Exchange Cap (19.99%).
• Complete the final valuation of the acquired interests and review by the Company's independent registered public accounting firm.
• SOD Sciences is required to record the assignment of the Test Interest with the USPTO and applicable foreign patent authorities within 30 days of the Closing Date.

Key Dates

Recommendation

The acquisition represents a strategic step with significant potential upside, particularly in expanding patient reach and revenue streams. However, the realization of these benefits is contingent on several factors, including the finalization of agreements, bankruptcy court approvals, and Nasdaq's continued listing review. The potential for dilution from preferred stock conversion also warrants caution. Therefore, a 'hold' recommendation is appropriate pending further clarity on these critical dependencies.

Keywords

pseudohypoxia, early-warning test, intellectual property, co-ownership, acquisition, sleep apnea, chronic disease, preferred stock